Wednesday, June 10, 2026

Patent intelligence · CN

CN 115003329

Parapoxvirus for conditioning and treating coronavirus infections

granted A61K 39/ 00 A IA61K 39/ 12 A IA61K 45/ 06 A IA61K 48/ 00 A I
Status granted
Pipeline programs 6
Years to expiry 16
Applicant portfolio 24
Patent details — CN 115003329
Jurisdiction
CN
Status
granted
Grant date
Sep 2, 2022
Expiration
Aug 28, 2042
CPC classes
A61K 39/ 00 A I, A61K 39/ 12 A I, A61K 45/ 06 A I, A61K 48/ 00 A I
View on Google Patents ↗

Quick answer

CN 115003329 (Parapoxvirus for conditioning and treating coronavirus infections) is held by BAYER HEALTHCARE AG. Status: granted. Granted Sep 2, 2022. Expires Aug 28, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
CPC classes
A61K 39/ 00 A I, A61K 39/ 12 A I, A61K 45/ 06 A I, A61K 48/ 00 A I, A61K/3912, A61K/39275

More from BAYER HEALTHCARE AG

Related pharmaceutical patents in our USPTO index.

  1. WO 2024052517

    USAGE MÉDICAL D'ANTICORPS ANTI-CCR8 ET PROGRAMME DE DOSAGE

    BAYER AG [DE] · Expires Mar 9, 2044

    granted
  2. CN 117186084

    Pranlerivir sulfonate, and pharmaceutical preparation, preparation method and application thereof in treatment of herpes virus

    BAYER HEALTHCARE AG · Expires Dec 3, 2043

    granted
  3. CN 115348859

    Ophthalmic formulations comprising n-[5-(aminosulfonyl)-4-methyl-1, 3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl) phenyl] acetamide hemihydrate

    BAYER HEALTHCARE AG · Expires Nov 10, 2042

    granted
  4. BR 112021015776

    Edição de gene para hemofilia a com expressão de fator viii melhorada

    BAYER HEALTHCARE LLC [US] · Expires Nov 4, 2041

    granted
  5. WO 2021152186

    ANTICORPS CCR8 POUR APPLICATIONS THÉRAPEUTIQUES

    BAYER AG [DE] · Expires Jul 31, 2041

    granted
  6. DE 102019218587

    Kontrastmittelbasierte Gefäßdarstellung

    BAYER AG [DE] · Expires May 28, 2041

    granted
  7. DE 102019218589

    Simultane Bilddarstellung von zwei unterschiedlichen funktionellen Bereichen

    BAYER AG [DE] · Expires May 28, 2041

    granted

Frequently asked questions

What is US patent 115003329?

CN 115003329 (Parapoxvirus for conditioning and treating coronavirus infections) is held by BAYER HEALTHCARE AG. Status: granted. Granted Sep 2, 2022. Expires Aug 28, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Who owns CN 115003329?

BAYER HEALTHCARE AG is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 24 pharmaceutical patents for this assignee.

When does CN 115003329 expire?

Our index shows an expiration date of Aug 28, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.